← All trials
NCT03508609
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 19, 2018
- Primary completion
- Sep 30, 2019
- Completion date
- Apr 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 20
- Arms / groups
- — / —
- Source
- AACT · ingestion pipeline
Sponsors
- Caladrius BiosciencesLead sponsor
- Cedars-Sinai Medical CenterCollaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Mayo ClinicCollaborator
- University of California, San FranciscoStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.